BioWorld

Aug. 26, 2005

View Archived Issues

Nastech Brings In $23M To Support PTH Nasal Program

Only a few weeks after withdrawing one public offering due to market conditions, Nastech Pharmaceutical Company Inc. did a complete turnaround, pricing more than 1.7 million shares on Thursday to raise $23.3 million. (BioWorld Today) Read More

Isis' ISIS 13650 Becomes First Drug In iCo's Pipeline

Read More

Merck's Lawsuit Liabilities Could Be Partnership Drain

Read More

Novavax Stock Jumps On Avian Flu Vaccine Success

Read More

Other News To Note

Read More